Marlborough biomanufacturer receives FDA approval for diabetes drug
PHOTO | Courtesy Google Maps
TheracosBio in Marlborough develops drugs for common diseases.
TheracosBio, a Marlborough-based drug manufacturer, received U.S. Food and Drug Administration approval for a new type 2 diabetes treatment.
The drug, called Brenzavvy, was approved after 23 clinical trials which enrolled more than 5,000 adults with type 2 diabetes, according to a press release from the company on Monday.
Brenzavvy, which is indicated to reduce blood glucose levels in adults with type 2 diabetes, is in a class of drugs called SGLT2 inhibitors It is intended to be used in combination with diet and exercise.
“Today's FDA approval represents a significant milestone for TheracosBio and provides an important treatment option to patients who suffer from type 2 diabetes,” Albert Collinson, president and CEO of TheracosBio, said in the press release.
The U.S. Centers for Disease Control reports more than 37 million Americans have diabetes, with 90-95% of those cases being type 2. TheracosBio’s focus is on development of new drugs for common illnesses, according to the company.
WBJ Web Partners
Most Recent
Most Recent
0 Comments